PMCPA Case
| Case number | AUTH/2207/2/09 |
|---|---|
| Case reference | Cephalon v ProStrakan (Promotion of Abstral) |
| Complainant | Cephalon (UK) Limited |
| Respondent/company | ProStrakan Ltd |
| Product(s) | Abstral (sublingual fentanyl citrate tablet) |
| Material/channel | Two leavepieces (MO17/0070 and MO17/0101) |
| Key issue | Claim “Rapid relief of breakthrough cancer pain from 10 minutes” held inconsistent with the Abstral SPC (which stated significantly superior relief from 15 minutes onwards) |
| Dates (received/completed if stated) | Received 11 February 2009; completed 16 March 2009 |
| Appeal | Not stated |
| Code year | Not stated |
| Breaches/clauses | Clause 3.2 |
| Sanctions | No explicit additional sanctions stated beyond the required undertaking/corrective actions described in the report |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Charter Member — Until 31 March
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499
One real case. One key lesson. Every week — free.